Sedation and safety of propofol for therapeutic endoscopic retrograde cholangiopancreatography.
BACKGROUND
Endoscopic retrograde cholangiopancreatography (ERCP) is the most complex gastrointestinal procedure, which needs patients' cooperation. The aim of this study was to observe the quality and safety of sedation with propofol in patients undergoing therapeutic ERCP.


METHODS
Seventy patients who had undergone therapeutic ERCP were randomly divided into two groups. One group,given intravenously propofol,and the other sedated with routine method,served as the control. Blood pressure,heart rate, oxygen saturation were monitored and cardiorespiratory event was observed. Patient cooperation, performance, recovery time and amnesia served as variables postoperation.


RESULTS
Blood pressure elevated in four patients in the propofol group, less than in the control group (P < 0.01). Seven patients showed decreased blood pressure after administration of propofol, but none in the control group (P < 0.01). Twelve patients in the control group showed mild or significant resistance, but none in the propofol group (P < 0.01). The time for performance in the propofol group (P < 0.05) was shorter than in the control group. Patient recovery was quicker in the propofol group than in the control group (P < 0.01). The degree of amnesia better in the propofol group than in the control group (P < 0.01). The degree of amnesia was also better in the propofol group than in the control group (P<0.01).


CONCLUSIONS
Propofol proves to be an excellent sedative for therapeutic ERCP. Being effective and safe, it shows a shorter ERCP duration but quick recovery and better amnesia. It is better than other routine sedatives.
Chen
Wei-Xing
WX
Digestive Department, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. chenwiexing@hotmail.com
Lin
Hui-Jia
HJ
Zhang
Wei-Fang
WF
Gu
Qing
Q
Zhong
Xiao-Qi
XQ
Yu
Chao-Hui
CH
Li
You-Ming
YM
Gu
Zhu-Ying
ZY
D000328:Adult; D000368:Aged; D000647:Amnesia / Q000139:chemically induced; D001794:Blood Pressure / Q000187:drug effects; D016022:Case-Control Studies; D002760:Cholangiopancreatography, Endoscopic Retrograde; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010349:Patient Compliance; D015742:Propofol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D020127:Recovery of Function; D012120:Respiration Disorders / Q000209:etiology; D013997:Time Factors
D006993:Hypnotics and Sedatives; D010100:Oxygen; D015742:Propofol